Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
BionetROCO:1784 -0.82%78 OCF Margin % is 8.29% as of Dec. 2025, which is 56% above its 10-year median of 5.32. GuruFocus rates ROCO:1784 with a GF Score™ of 78/100 and a GF Value™ of NT$79.64 (Modestly Undervalued). The stock has 6 warning signs investors should review. Among 203 Medical Diagnostics & Research companies, Bionet ranks better than 64.04% on this metric.
The historical rank and industry rank for Bionet's OCF Margin % or its related term are showing as below:
ROCO:1784'
s OCF Margin % Range Over the Past 10 Years
Min: -3.57 Med: 5.32 Max: 14.44
Current: 11.97
During the past 13 years, the highest OCF Margin % of Bionet was 14.44%. The lowest was -3.57%. And the median was 5.32%.
ROCO:1784's OCF Margin % is ranked better than 64.04% of 203
companies
in the Medical Diagnostics & Research industry
Industry Median: 4.84
vs ROCO:1784: 11.97
Bionet OCF Margin % Related Terms
Bionet OCF Margin % Historical Data
* Premium members only.
The historical data trend for Bionet's OCF Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ROCO:1784 vs TMO, DHR, IDXX: OCF Margin % Comparison
For the Diagnostics & Research subindustry, Bionet's OCF Margin %, along with its competitors' market caps and OCF Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Bionet OCF Margin % vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Bionet's OCF Margin % distribution charts can be found below:
* The bar in red indicates where Bionet's OCF Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Bionet (ROCO:1784) has a OCF Margin % of 8.29% as of Dec. 2025. OCF Margin is the ratio of Cash Flow from Operations to Total Revenue. View historical data on Bionet and its competitors. This is 56% above median its historical median of 5.32. According to the industry distribution chart, Bionet ranks #73 out of 203 companies in the Medical Diagnostics & Research industry, placing it in the top 36%.
Is Bionet's OCF Margin % too high?
Bionet's current OCF Margin % of 8.29% is 56% above median its 10-year median of 5.32. The Medical Diagnostics & Research industry median OCF Margin % is 4.84. Bionet's value of 8.29% is 71.3% above this industry median. Based on the distribution chart, Bionet ranks #73 out of 203 companies in the Medical Diagnostics & Research industry, which is above the industry midpoint. Overall, Bionet has a GF Score™ of 78/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Bionet's OCF Margin % compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Bionet ranks #73 out of 203 companies for OCF Margin %. This puts Bionet in the upper half of its industry. The industry median OCF Margin % is 4.84. Bionet's value of 8.29% is 71.3% above this benchmark. While the company's 10-year median is 5.32 vs. the industry median of 4.84, Bionet has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good OCF Margin % for a Medical Diagnostics & Research company?
The median OCF Margin % among Medical Diagnostics & Research companies is 4.84, based on 203 companies in the industry. Companies in the top quartile (top 25%) have a OCF Margin % significantly above this median, while those in the bottom quartile fall well below. However, OCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Bionet's current OCF Margin % of 8.29% is 71.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high OCF Margin % mean?
A high OCF Margin % can signal that a stock is expensive relative to its fundamentals. OCF Margin is the ratio of Cash Flow from Operations to Total Revenue. View historical data on Bionet and its competitors. For the Medical Diagnostics & Research industry, the median OCF Margin % is 4.84 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Bionet's current OCF Margin % is 8.29%, which is 56% above median its own 10-year median of 5.32. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Bionet stock overvalued right now?
Based on GuruFocus' analysis, Bionet (ROCO:1784) is currently considered Modestly Undervalued. The stock's GF Value™ is NT$79.64, compared to a current price of NT$60.30 — trading 24.3% below its estimated fair value. The current OCF Margin % is 8.29%, which is 56% above median its 10-year median of 5.32 and 71.3% above the Medical Diagnostics & Research industry median of 4.84. Bionet's overall GF Score™ is 78/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is OCF Margin % calculated?
OCF Margin % is calculated from a company's financial statements. For Bionet (ROCO:1784), the current OCF Margin % is 8.29% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Bionet (ROCO:1784) Overvalued in 2026?
Based on GuruFocus' analysis, Bionet stock appears to be undervalued.
The current stock price of NT$60.30 is trading 24.3% below its estimated GF Value™ of NT$79.64.
GuruFocus considers Bionet to be Modestly Undervalued.
Key valuation signals for ROCO:1784:
OCF Margin %: 8.29% (56% above median its 10-year median of 5.32)
GF Value™: NT$79.64 vs. price of NT$60.30 (24.3% below fair value)
Industry Position: 71.3% above the Medical Diagnostics & Research median (#73 of 203)
No single metric tells the full story. See the ROCO:1784 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Bionet Corp provides blood bank and stem cell services. It is a preservation center for stem cells such as Umbilical Cord Mesenchymal Stem Cells and Dental Pulp Stem Cell Stem.
78GF Score
Get the complete analysis for ROCO:1784
OCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:1784 has been successfully added to your 
